Dear Investors,
The opioid crisis continues to create significant demand for more accessible, patient-friendly treatment options. While long-acting injectable buprenorphine has demonstrated clinical value, adoption remains limited by cost, injection experience, and other barriers to access.
Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive virtual investor briefing featuring Frenelle PBC, a biopharma company developing FRN01, a next-generation 30-day subcutaneous buprenorphine injection for the treatment of Opioid Use Disorder (OUD).
FRN01 is built on Frenelle Pharma’s proprietary Faros™ long-acting injectable technology, a platform developed over more than a decade to deliver consistent drug release through small-gauge needles with the potential to reduce injection-site pain.
Why Investors Are Taking Notice
Massive, Underpenetrated Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, yet reaches less than 10% of patients treated for OUD.
Differentiated Product — FRN01 is a once-monthly subcutaneous injection designed to address key patient and access barriers associated with existing treatments.
De-Risked Platform — Frenelle’s Faros™ technology has been clinically validated, with FRN01 having demonstrated formulation proof of concept.
Experienced Team — Frenelle brings an experienced drug development team and Mayo Clinic addiction medicine expertise.
